Home » Newsletters » BioWorld Science

BioWorld Science

May 16, 2017

View Archived Issues

Improved respiratory pathology associated to Pompe disease with the new vector AAV-B1-GAA

Complement factor B targeted with IONIS-FB-LRX for age-related macular degeneration

Otsuka and Teva enter licensing agreement for fremanezumab in Japan

Phase III NEURO-TTR study of inotersen meets both primary endpoints

Phase I results for tetravalent dengue vaccine TV-003 in flavivirus-experienced subjects

Novel nickel catalyst transforms unrefined hydrocarbons and carbon dioxide into valuable fatty acids

FDA accepts Aerie Pharmaceuticals' NDA for Rhopressa

Biogen acquires Cirara from Remedy Pharmaceuticals

Cytokinetics' CK-2127107 named FDA orphan drug for SMA

Quadruplex sgRNAs/saCas9 AAV gene therapy results in successful HIV-1 provirus excision in vivo

FDA grants breakthrough therapy designation to entrectinib

Imara's IMR-687 awarded FDA rare pediatric disease designation

Immunomic Therapeutics and Annias enter license agreement for cancer immunotherapy technology

Development of cell-mediated gene therapy Invossa updated at ASCGT

New prophylactic vaccine against influenza A and B viruses

Takeda splits off part of its pharmaceutical research businesses to new company

Improved polymerase-1 inhibitor RAM-589.555 synthesized for multiple sclerosis treatment

Advaxis reports data from phase I study of axalimogene filolisbac

Enterin initiates phase I/IIa study of synthetic squalamine derivative for Parkinson's disease

Glenmark Pharmaceuticals cleared to begin phase I study of GBR-1342

Boehringer Ingelheim plans phase II trial for PXS-4728A in second indication

VV-2003, an ORAI1 calcium channel inhibitor for the treatment of colitis

BiomX raises funds to support development of mircrobiome therapeutics

Formation Biologics begins phase I/IIa trial of AVID-100

Amicus Therapeutics reports results from phase I/II study in Pompe disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...